The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats
about
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic NephropathyRho kinase proteins--pleiotropic modulators of cell survival and apoptosisRhoA/Rho kinase mediates TGF-β1-induced kidney myofibroblast activation through Poldip2/Nox4-derived reactive oxygen species.Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse.Aberrant ROCK activation promotes the development of type I diabetes in NOD miceMicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy.Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient ratsActivation of RhoA in podocytes induces focal segmental glomerulosclerosis.Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease.Opposite Expression of SPARC between the Liver and Pancreas in Streptozotocin-Induced Diabetic RatsMitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cellsCombined effect of hydrogen sulphide donor and losartan in experimental diabetic nephropathy in ratsPodocyte-specific loss of Cdc42 leads to congenital nephropathyRenoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3.Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic ratsFyn Mediates High Glucose-Induced Actin Cytoskeleton Reorganization of Podocytes via Promoting ROCK Activation In Vitro.Angiotensin (1-7)/Mas receptor axis activation ameliorates the changes in fatty acid composition in diabetic rats with nephropathy.Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy.Amelioration of albuminuria in ROCK1 knockout mice with streptozotocin-induced diabetic kidney diseaseRedox control of renal function and hypertension.Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney diseaseMineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.Targeting of Rho kinase ameliorates impairment of diabetic endothelial function in intrarenal artery.Diabetes and Kidney Disease: Role of Oxidative Stress.Experimental models for nephropathy.Long-term diabetic complications may be ameliorated by targeting Rho kinase.What are new avenues for renal protection, in addition to RAAS inhibition?Smoking in diabetic nephropathy: sparks in the fuel tank?Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?Pathophysiology of the diabetic kidney.Rho kinase inhibition in diabetic kidney disease.Role of Rho-GTPases and their regulatory proteins in glomerular podocyte function.Most appropriate animal models to study the efficacy of statins: a systematic review.Rodent animal models: from mild to advanced stages of diabetic nephropathy.Novel effective drugs for diabetic kidney disease? or not?Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytesThe influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone.Pleiotropic Effects of Statins on the Cardiovascular System.Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production
P2860
Q26784039-8D90EA7D-7529-49A1-BDDF-51D87B502FCAQ27023537-EE97F468-DAC8-4D57-AD85-2FFB20AC119FQ33913063-8EF2C78A-2122-4F87-8CB2-557B54A64432Q34024334-91F73E97-2EAF-4146-AE7E-3D3AB387240AQ34540407-7F52A4A5-C88A-4A27-9862-AB8E40D313BDQ34719895-B3191045-1818-4530-ABA1-CA466242506AQ35179736-A332026A-8C56-4B9A-A1E9-B05688FF6D44Q35210190-684C16F9-B896-4AB9-A7D0-A7829B9BE886Q35450699-16381BCC-7E1D-48A4-B22D-6AE4B02E6FFEQ35674489-9E1FA328-FD8C-4BA7-A7AC-0181890C4BAEQ35754670-C75FDDFF-E5D3-435E-8F77-674D8479F606Q35896349-66323A09-ECB3-4AEE-A1E1-E68F825678A5Q36050935-A6E97E2B-5500-4ED6-9D18-35DD69501FB0Q36138508-4C4B7632-EAA3-42EB-9ED0-BA74B3204799Q36287742-CA0BAAB2-AD2D-47A8-8E08-D44FBC8CEE74Q36531604-1D5AB605-EA14-4DAA-8268-97387E264777Q36890435-47B938E2-8F12-48D9-BD12-8818ADE9BEFFQ36891626-5AE55103-771F-447F-AD74-214660DD6E9DQ36953372-D2CF83FA-5EBA-4574-B793-7F5C5360AB04Q36970633-C9B6C064-3078-4B9C-A229-08EFCD73D5A4Q37188464-05CA6EDB-5590-4038-9FE0-ADE33C621CC2Q37190283-15EBCECC-E621-43B2-9260-E5845B5DDEE6Q37291276-AA36CC89-0E1C-417E-8DC8-CCAF976B2229Q37349206-2B74CB60-BA4B-4492-9AAB-A136C23350C2Q37363579-4CA1D3FA-2C3E-4067-8155-264C86BAA642Q37838899-163F845C-A037-439E-8666-0176272E269EQ37980677-1D7D0AAF-1592-41E2-8EFF-ABF5AACEC2D0Q38072702-9EB89DA7-8522-4450-9C80-DA3E18F7116EQ38092960-72472264-12A3-49ED-9F6D-EBEAA7D3298CQ38111707-8679E911-A80D-4986-8DAD-7109E1AE2523Q38117171-372A7915-8DAB-4408-8ECE-E6967E647D65Q38154296-62D8078D-EEB1-4D8D-AAF6-A9ECDB4BEFD9Q38234426-48F667BF-DD53-4B83-9D5E-2DF54599D31CQ38242389-EBD3D965-12A8-40A7-AB10-7817201770C5Q38265818-220F9C64-14A0-41D3-B037-A9D0C6A15564Q38332511-40252988-3A45-4CA7-8418-2E0802DA344EQ38662676-BCAABF4A-7583-4DBB-8211-9000DC938B49Q39069187-EE9CED59-4DFA-4DB4-9235-90281DFAFC34Q39173742-4AD17E52-FBD6-4037-9489-53DF47AAE734Q39431398-EA4F6B1C-8C99-45A2-AE6A-2B8EB87AFE09
P2860
The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats
description
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Juli 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/07/30)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/07/30)
@nl
наукова стаття, опублікована в липні 2007
@uk
مقالة علمية (نشرت في 30-7-2007)
@ar
name
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@ast
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@en
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@nl
type
label
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@ast
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@en
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@nl
prefLabel
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@ast
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@en
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@nl
P2093
P3181
P1476
The Rho-kinase inhibitor, fasu ...... ozotocin-induced diabetic rats
@en
P2093
Atsushi Gojo
Hideaki Kurata
Kanta Taniguchi
Kazunori Utsunomiya
Naoko Tajima
Shoh Ishizawa
Tamotsu Yokota
Yasushi Kanazawa
P304
P3181
P356
10.1016/J.EJPHAR.2007.04.011
P407
P577
2007-07-30T00:00:00Z